|
AU2903999A
(en)
*
|
1998-03-12 |
1999-09-27 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Methods and compositions of chemokine-tumor antigen fusion proteins as cancer vaccines
|
|
CN1635876A
(zh)
|
2000-02-04 |
2005-07-06 |
杜克大学 |
人免疫缺陷病毒疫苗
|
|
WO2001083535A2
(en)
*
|
2000-05-02 |
2001-11-08 |
Simon Fraser University |
Polypeptides for use as a vaccine and/or treatment for hiv infection
|
|
AUPS065002A0
(en)
|
2002-02-20 |
2002-03-14 |
Immunaid Pty Ltd |
Strategy for retroviral immunotherapy
|
|
US20030228320A1
(en)
*
|
2000-08-18 |
2003-12-11 |
Ashdown Martin Leonard |
Retroviral immunotherapy
|
|
AU2001291050A1
(en)
|
2000-09-15 |
2002-03-26 |
The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Viral chemokine-tumur antigen fusion proteins
|
|
AU2001291049A1
(en)
|
2000-09-15 |
2002-03-26 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health, Office Of Technology Transfer |
Defensin-antigen fusion proteins
|
|
WO2002064154A2
(en)
*
|
2001-02-15 |
2002-08-22 |
The Government Of The United States Of America, Asrepresented By The Secretary Of The Department Of Health And Human Services |
Methods and compositions for inhibiting hiv-coreceptor interactions
|
|
AUPS054702A0
(en)
*
|
2002-02-14 |
2002-03-07 |
Immunaid Pty Ltd |
Cancer therapy
|
|
CA2505583C
(en)
*
|
2002-12-03 |
2014-07-15 |
University Of Massachusetts |
Polyvalent, primary hiv-1 glycoprotein dna vaccines and vaccination methods
|
|
MXPA05013334A
(es)
*
|
2003-06-12 |
2006-05-19 |
Vexgen Inc |
Glucoproteinas de envoltura de vih-1 que tienen estructuras de disulfuro inusuales.
|
|
US8076060B2
(en)
*
|
2003-08-04 |
2011-12-13 |
Emil William Chynn |
Vaccination and immunotherapy as new therapeutic modalities in the treatment of glaucoma
|
|
DK1692516T3
(da)
|
2003-10-24 |
2011-02-28 |
Immunaid Pty Ltd |
Terapifremgangsmåde
|
|
US20080248022A1
(en)
*
|
2004-09-08 |
2008-10-09 |
Immunaid Pty Ltd |
Therapeutic Strategy for Treating Autoimmune and Degenerative Diseases
|
|
EP2742951B1
(en)
*
|
2004-09-14 |
2016-02-03 |
Argos Therapeutics, Inc. |
Strain independent amplification of HIV polynucleotides
|
|
CN101313216A
(zh)
*
|
2005-09-22 |
2008-11-26 |
普洛茨股份有限公司 |
酵母突变体中产生的糖基化多肽及其使用方法
|
|
US8221981B2
(en)
|
2007-07-30 |
2012-07-17 |
Argos Therapeutics, Inc. |
Primers and probes for the amplification and detection of HIV Gag, Rev and Nef polynucleotides
|
|
CA2735724C
(en)
|
2008-06-19 |
2018-07-24 |
Variation Biotechnologies Inc. |
Compositions and methods for treating influenza
|
|
WO2010135781A1
(en)
|
2009-05-27 |
2010-12-02 |
Immunaid Pty Ltd |
Methods of treating diseases
|
|
CA2803282C
(en)
|
2009-07-06 |
2018-05-01 |
David E. Anderson |
Methods for preparing vesicles and formulations produced therefrom
|
|
ES2573427T3
(es)
|
2009-07-06 |
2016-06-07 |
Variation Biotechnologies Inc. |
Procedimientos para preparar vesículas y formulaciones producidas a partir de las mismas
|
|
EP2550362B1
(en)
|
2010-03-25 |
2017-01-04 |
Oregon Health&Science University |
Cmv glycoproteins and recombinant vectors
|
|
JP6119030B2
(ja)
|
2010-07-06 |
2017-04-26 |
ヴァリエーション バイオテクノロジーズ インコーポレイテッド |
インフルエンザを治療するための組成物及び方法
|
|
EP2663327A4
(en)
|
2011-01-13 |
2015-12-02 |
Variation Biotechnologies Inc |
COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
|
|
SI2691530T1
(en)
|
2011-06-10 |
2018-08-31 |
Oregon Health & Science University |
Cmv glycoproteins and recombinant vectors
|
|
US20130189754A1
(en)
|
2011-09-12 |
2013-07-25 |
International Aids Vaccine Initiative |
Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
|
|
US9402894B2
(en)
|
2011-10-27 |
2016-08-02 |
International Aids Vaccine Initiative |
Viral particles derived from an enveloped virus
|
|
US20140356399A1
(en)
|
2012-01-12 |
2014-12-04 |
Variation Biotechnologies, Inc. |
Compositions and methods for treating viral infections
|
|
CA2894467A1
(en)
|
2012-01-27 |
2013-08-01 |
Variation Biotechnologies Inc. |
Methods for preparing thermostable compositions comprising a lipid component and thermolabile therapeutic agents
|
|
EP2679596B1
(en)
|
2012-06-27 |
2017-04-12 |
International Aids Vaccine Initiative |
HIV-1 env glycoprotein variant
|
|
US9951106B2
(en)
|
2012-12-04 |
2018-04-24 |
University Of Maryland, Baltimore |
Recombinant fusion protein comprising HIV gp120 linked to an enhancing CD4 binding site mAb
|
|
EP2848937A1
(en)
|
2013-09-05 |
2015-03-18 |
International Aids Vaccine Initiative |
Methods of identifying novel HIV-1 immunogens
|
|
US10058604B2
(en)
|
2013-10-07 |
2018-08-28 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
|
EP3069730A3
(en)
|
2015-03-20 |
2017-03-15 |
International Aids Vaccine Initiative |
Soluble hiv-1 envelope glycoprotein trimers
|
|
US9931394B2
(en)
|
2015-03-23 |
2018-04-03 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|